Allogene Therapeutics Inc (ALLO)

$2.10 -0.02 (-0.94%)
Market Cap 742.08M
Revenue (ttm) 0.00
Net Income (ttm) -190.89M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 6,540,058
Avg Vol 8,528,048
Day's Range N/A - N/A
Shares Out 345.16M
Stochastic %K 54%
Beta 0.46
Analysts Strong Sell
Price Target $7.99

Company Profile

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 2700
Address:
210 East Grand Avenue, South San Francisco, United States
AlphaFoundry
AlphaFoundry Jul. 9 at 1:05 PM
Last 60m on Coinbase spot: Gainers: $BOBBOB +4.44% $SENT +2.95% $ALLO +2.1% Losers: $NEX -12.27% $KAITO -3.25% $GWEI -2.33% Volume still led by $BTC. Rotation looks selective, with a few small caps catching bids while weaker names get hit hard.
0 · Reply
Wolfietrader
Wolfietrader Jul. 8 at 7:14 PM
$ALLO a Talking Heads on Fox business just said ALLO is a takeover target and he’s a strong buyer right now
2 · Reply
NasdaqNavigatorrr
NasdaqNavigatorrr Jul. 8 at 5:53 PM
Last 60m on Coinbase spot: $ALLO +6.15%, $APE +6.04%, $YFI +4.5% leading the tape. On the downside: $NEON -9.99%, $EDGEX -8.69%, $KAIO -4.42%. Volume still anchored by the majors: $BTC 34.24M, $ETH still heavy. Rotation feels active, but the move is still very selective.
0 · Reply
Filvul
Filvul Jul. 8 at 2:00 PM
$ALLO
0 · Reply
LVUP
LVUP Jul. 8 at 5:08 AM
$ALLO
0 · Reply
AS1980
AS1980 Jul. 7 at 1:43 PM
$ALLO endless..
0 · Reply
dflipflop
dflipflop Jul. 6 at 10:59 PM
$ALLO took an initial position here today.
0 · Reply
Unburdened
Unburdened Jul. 2 at 3:17 PM
$ALLO another great day
0 · Reply
alwayscheaper
alwayscheaper Jun. 30 at 8:46 PM
$ALLO feels like shorts have re entered today 😕
0 · Reply
Filvul
Filvul Jun. 30 at 8:21 PM
$ALLO Amazing!
0 · Reply
Latest News on ALLO
Allogene Therapeutics Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 30, 2026, 4:00 PM EDT - 9 days ago

Allogene Therapeutics Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Allogene Therapeutics Transcript: AGM 2026

Jun 18, 2026, 11:00 AM EDT - 21 days ago

Allogene Therapeutics Transcript: AGM 2026

Allogene Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 8:10 AM EDT - 5 weeks ago

Allogene Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Allogene Therapeutics says Zachary Roberts to succeed David Chang as CEO

2026-05-28T21:22:23.000Z - 6 weeks ago

Allogene Therapeutics says Zachary Roberts to succeed David Chang as CEO

Allogene Therapeutics Announces Planned CEO Succession

May 28, 2026, 5:02 PM EDT - 6 weeks ago

Allogene Therapeutics Announces Planned CEO Succession

Allogene Therapeutics Proxy statement: Proxy filing

May 28, 2026, 8:00 AM EDT - 6 weeks ago

Allogene Therapeutics Proxy statement: Proxy filing

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

May 26, 2026, 8:30 AM EDT - 6 weeks ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Allogene Therapeutics Proxy statement: Proxy filing

May 21, 2026, 8:00 AM EDT - 7 weeks ago

Allogene Therapeutics Proxy statement: Proxy filing

Allogene Therapeutics Slides: Corporate presentation

May 16, 2026, 7:00 AM EDT - 7 weeks ago

Allogene Therapeutics Slides: Corporate presentation

Allogene Therapeutics ends China cell therapy deal with Overland

May 13, 2026, 5:05 PM EDT - 2 months ago

Allogene Therapeutics ends China cell therapy deal with Overland

Allogene Therapeutics reports Q1 EPS (18c), consensus (18c)

2026-05-13T21:04:53.000Z - 2 months ago

Allogene Therapeutics reports Q1 EPS (18c), consensus (18c)

Allogene Therapeutics increases 2026 operating cash expense guidance

2026-05-13T21:01:55.000Z - 2 months ago

Allogene Therapeutics increases 2026 operating cash expense guidance

Allogene Therapeutics Earnings Call Transcript: Q1 2026

May 13, 2026, 5:00 PM EDT - 2 months ago

Allogene Therapeutics Earnings Call Transcript: Q1 2026

Allogene Therapeutics Earnings release: Q1 2026

May 13, 2026, 5:00 PM EDT - 2 months ago

Allogene Therapeutics Earnings release: Q1 2026

Allogene Therapeutics Quarterly report: Q1 2026

May 13, 2026, 5:00 PM EDT - 2 months ago

Allogene Therapeutics Quarterly report: Q1 2026

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

May 13, 2026, 4:02 PM EDT - 2 months ago

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

May 6, 2026, 8:30 AM EDT - 2 months ago

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Allogene Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Allogene Therapeutics Proxy statement: Proxy filing

Allogene Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Allogene Therapeutics Proxy statement: Proxy filing

Allogene Therapeutics expands Phase 2 ALPHA3 trial to South Korea, Australia

2026-04-21T12:50:39.000Z - 2 months ago

Allogene Therapeutics expands Phase 2 ALPHA3 trial to South Korea, Australia

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

Apr 21, 2026, 8:30 AM EDT - 2 months ago

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

Apr 20, 2026, 8:30 AM EDT - 2 months ago

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

Allogene Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 2 months ago

Allogene Therapeutics Proxy statement: Proxy filing

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

Apr 16, 2026, 4:01 PM EDT - 3 months ago

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

Allogene Therapeutics price target lowered to $11 from $12 at H.C. Wainwright

2026-04-16T10:18:20.000Z - 3 months ago

Allogene Therapeutics price target lowered to $11 from $12 at H.C. Wainwright

Allogene Therapeutics upgraded to Neutral from Underweight at JPMorgan

2026-04-16T09:26:14.000Z - 3 months ago

Allogene Therapeutics upgraded to Neutral from Underweight at JPMorgan

Allogene Therapeutics price target raised to $10 from $6 at Jefferies

2026-04-15T16:06:54.000Z - 3 months ago

Allogene Therapeutics price target raised to $10 from $6 at Jefferies

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

Apr 15, 2026, 8:30 AM EDT - 3 months ago

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

Allogene Therapeutics 87.5M share Spot Secondary priced at $2.00

2026-04-15T02:00:15.000Z - 3 months ago

Allogene Therapeutics 87.5M share Spot Secondary priced at $2.00

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

Apr 14, 2026, 9:50 PM EDT - 3 months ago

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein

2026-04-14T11:51:26.000Z - 3 months ago

Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein

Allogene Therapeutics price target raised to $9 from $7 at Baird

2026-04-14T11:46:22.000Z - 3 months ago

Allogene Therapeutics price target raised to $9 from $7 at Baird

Allogene Therapeutics price target raised to $12 from $8 at H.C. Wainwright

2026-04-14T10:15:55.000Z - 3 months ago

Allogene Therapeutics price target raised to $12 from $8 at H.C. Wainwright

Allogene Therapeutics price target raised to $8 from $5 at Citizens

2026-04-14T09:50:12.000Z - 3 months ago

Allogene Therapeutics price target raised to $8 from $5 at Citizens

Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments

2026-04-13T20:45:37.000Z - 3 months ago

Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments

CLLS

Allogene Therapeutics announces $175M common stock offering

2026-04-13T20:35:10.000Z - 3 months ago

Allogene Therapeutics announces $175M common stock offering

Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

Apr 13, 2026, 4:01 PM EDT - 3 months ago

Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

Allogene Therapeutics Transcript: Study result

Apr 13, 2026, 8:30 AM EDT - 3 months ago

Allogene Therapeutics Transcript: Study result

Allogene Therapeutics Press release: Study result

Apr 13, 2026, 8:30 AM EDT - 3 months ago

Allogene Therapeutics Press release: Study result

Allogene Therapeutics Slides: Study result

Apr 13, 2026, 8:30 AM EDT - 3 months ago

Allogene Therapeutics Slides: Study result

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

Apr 13, 2026, 8:00 AM EDT - 3 months ago

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

NTRA

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

Apr 13, 2026, 7:30 AM EDT - 3 months ago

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

Apr 10, 2026, 4:02 PM EDT - 3 months ago

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

Allogene Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 5:00 PM EDT - 4 months ago

Allogene Therapeutics Earnings Call Transcript: Q4 2025

Allogene Therapeutics Annual report: Q4 2025

Mar 12, 2026, 5:00 PM EDT - 4 months ago

Allogene Therapeutics Annual report: Q4 2025

Allogene Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 5:00 PM EDT - 4 months ago

Allogene Therapeutics Earnings release: Q4 2025

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Mar 12, 2026, 4:02 PM EDT - 4 months ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Allogene Therapeutics Slides: Corporate presentation

Mar 12, 2026, 4:00 PM EDT - 4 months ago

Allogene Therapeutics Slides: Corporate presentation

Allogene Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:50 AM EST - 4 months ago

Allogene Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

Mar 2, 2026, 8:30 AM EST - 4 months ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

Allogene Therapeutics Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

Feb 18, 2026, 12:15 PM EST - 5 months ago

Allogene Therapeutics Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

Jan 8, 2026, 8:30 AM EST - 6 months ago

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

Dec 15, 2025, 5:39 PM EST - 7 months ago

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

CLLS

Allogene Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 12:00 PM EST - 7 months ago

Allogene Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Allogene Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 5:00 AM EST - 8 months ago

Allogene Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Allogene Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 4:30 PM EST - 8 months ago

Allogene Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Allogene Therapeutics Slides: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 4:30 PM EST - 8 months ago

Allogene Therapeutics Slides: TD Cowen Immunology and Inflammation Summit

Allogene Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

Allogene Therapeutics Earnings Call Transcript: Q3 2025

Allogene Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

Allogene Therapeutics Quarterly report: Q3 2025

Allogene Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

Allogene Therapeutics Earnings release: Q3 2025

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

Nov 6, 2025, 4:05 PM EST - 8 months ago

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting

Nov 3, 2025, 9:04 AM EST - 8 months ago

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting

Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update

Oct 30, 2025, 8:30 AM EDT - 9 months ago

Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics Transcript: Citi's SMID Call Series 2025

Oct 2, 2025, 1:00 PM EDT - 10 months ago

Allogene Therapeutics Transcript: Citi's SMID Call Series 2025

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

Aug 27, 2025, 8:30 AM EDT - 11 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

Allogene Therapeutics Earnings Call Transcript: Q2 2025

Aug 13, 2025, 5:00 PM EDT - 11 months ago

Allogene Therapeutics Earnings Call Transcript: Q2 2025

Allogene Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 5:00 PM EDT - 11 months ago

Allogene Therapeutics Quarterly report: Q2 2025

Allogene Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 5:00 PM EDT - 11 months ago

Allogene Therapeutics Earnings release: Q2 2025

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Aug 13, 2025, 4:05 PM EDT - 11 months ago

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics Transcript: Study Result

Aug 1, 2025, 11:00 AM EDT - 1 year ago

Allogene Therapeutics Transcript: Study Result

Allogene Therapeutics Press release: Study Result

Aug 1, 2025, 11:00 AM EDT - 1 year ago

Allogene Therapeutics Press release: Study Result

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Allogene Therapeutics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

Allogene Therapeutics Slides: Corporate Presentation

Allogene Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 4:55 PM EDT - 1 year ago

Allogene Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Jun 1, 2025, 10:45 AM EDT - 1 year ago

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Allogene Therapeutics Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 27, 2025, 12:30 PM EDT - 1 year ago

Allogene Therapeutics Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

May 22, 2025, 5:17 PM EDT - 1 year ago

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

Allogene Therapeutics Earnings Call Transcript: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Allogene Therapeutics Earnings Call Transcript: Q1 2025

Allogene Therapeutics Quarterly report: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Allogene Therapeutics Quarterly report: Q1 2025

Allogene Therapeutics Earnings release: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Allogene Therapeutics Earnings release: Q1 2025

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

May 13, 2025, 4:05 PM EDT - 1 year ago

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

Allogene Therapeutics Slides: Corporate Presentation

May 12, 2025, 6:00 PM EDT - 1 year ago

Allogene Therapeutics Slides: Corporate Presentation

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

May 6, 2025, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Allogene Therapeutics Proxy statement: Proxy Filing

Allogene Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Allogene Therapeutics Proxy statement: Proxy Filing

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 10:12 AM EDT - 1 year ago

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Apr 7, 2025, 8:30 AM EDT - 1 year ago

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Allogene Therapeutics Earnings Call Transcript: Q4 2024

Mar 13, 2025, 5:00 PM EDT - 1 year ago

Allogene Therapeutics Earnings Call Transcript: Q4 2024

Allogene Therapeutics Annual report: Q4 2024

Mar 13, 2025, 5:00 PM EDT - 1 year ago

Allogene Therapeutics Annual report: Q4 2024

Allogene Therapeutics Earnings release: Q4 2024

Mar 13, 2025, 5:00 PM EDT - 1 year ago

Allogene Therapeutics Earnings release: Q4 2024

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Mar 13, 2025, 4:02 PM EDT - 1 year ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Allogene Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 11:50 AM EST - 1 year ago

Allogene Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Mar 3, 2025, 8:30 AM EST - 1 year ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Allogene Therapeutics Announces Participation in March Investor Conference

Feb 26, 2025, 8:30 AM EST - 1 year ago

Allogene Therapeutics Announces Participation in March Investor Conference

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Feb 25, 2025, 4:10 PM EST - 1 year ago

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Feb 13, 2025, 4:30 PM EST - 1 year ago

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Allogene Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 3:20 PM EST - 1 year ago

Allogene Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Jan 28, 2025, 8:30 AM EST - 1 year ago

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Allogene Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 6:00 PM EST - 1 year ago

Allogene Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Allogene Therapeutics Slides: FY 2025

Jan 15, 2025, 6:00 PM EST - 1 year ago

Allogene Therapeutics Slides: FY 2025

Allogene Therapeutics Slides: Corporate Presentation

Jan 12, 2025, 6:00 PM EST - 1 year ago

Allogene Therapeutics Slides: Corporate Presentation

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Dec 12, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Allogene Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 8:00 AM EST - 1 year ago

Allogene Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Allogene Therapeutics Transcript: JMP Hematology and Oncology Summit 2024

Dec 2, 2024, 11:00 AM EST - 1 year ago

Allogene Therapeutics Transcript: JMP Hematology and Oncology Summit 2024

Allogene Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 6:30 AM EST - 1 year ago

Allogene Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Allogene Therapeutics Announces Participation in December Investor Conferences

Nov 19, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Announces Participation in December Investor Conferences

Allogene Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 8:35 AM EST - 1 year ago

Allogene Therapeutics Transcript: Stifel 2024 Healthcare Conference

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Nov 18, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Allogene Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 5:00 PM EST - 1 year ago

Allogene Therapeutics Earnings Call Transcript: Q3 2024

Allogene Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 5:00 PM EST - 1 year ago

Allogene Therapeutics Quarterly report: Q3 2024

Allogene Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 5:00 PM EST - 1 year ago

Allogene Therapeutics Earnings release: Q3 2024

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Nov 7, 2024, 4:02 PM EST - 1 year ago

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Nov 7, 2024, 10:00 AM EST - 1 year ago

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 5, 2024, 9:10 AM EST - 1 year ago

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Oct 2, 2024, 4:11 PM EDT - 1 year ago

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Allogene Therapeutics Transcript: Goldman Sachs Cell Therapy Day

Oct 1, 2024, 1:00 PM EDT - 1 year ago

Allogene Therapeutics Transcript: Goldman Sachs Cell Therapy Day

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Allogene Therapeutics Transcript: Baird 2024 Global Healthcare Conference

Sep 11, 2024, 9:40 AM EDT - 1 year ago

Allogene Therapeutics Transcript: Baird 2024 Global Healthcare Conference

Allogene Therapeutics Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 13, 2024, 10:00 AM EDT - 2 years ago

Allogene Therapeutics Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Allogene Therapeutics Earnings Call Transcript: Q2 2024

Aug 7, 2024, 5:00 PM EDT - 2 years ago

Allogene Therapeutics Earnings Call Transcript: Q2 2024

Allogene Therapeutics Quarterly report: Q2 2024

Aug 7, 2024, 5:00 PM EDT - 2 years ago

Allogene Therapeutics Quarterly report: Q2 2024

Allogene Therapeutics Earnings release: Q2 2024

Aug 7, 2024, 5:00 PM EDT - 2 years ago

Allogene Therapeutics Earnings release: Q2 2024

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Aug 7, 2024, 4:02 PM EDT - 2 years ago

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Jul 31, 2024, 8:30 AM EDT - 2 years ago

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Jul 1, 2024, 8:30 AM EDT - 2 years ago

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

AlphaFoundry
AlphaFoundry Jul. 9 at 1:05 PM
Last 60m on Coinbase spot: Gainers: $BOBBOB +4.44% $SENT +2.95% $ALLO +2.1% Losers: $NEX -12.27% $KAITO -3.25% $GWEI -2.33% Volume still led by $BTC. Rotation looks selective, with a few small caps catching bids while weaker names get hit hard.
0 · Reply
Wolfietrader
Wolfietrader Jul. 8 at 7:14 PM
$ALLO a Talking Heads on Fox business just said ALLO is a takeover target and he’s a strong buyer right now
2 · Reply
NasdaqNavigatorrr
NasdaqNavigatorrr Jul. 8 at 5:53 PM
Last 60m on Coinbase spot: $ALLO +6.15%, $APE +6.04%, $YFI +4.5% leading the tape. On the downside: $NEON -9.99%, $EDGEX -8.69%, $KAIO -4.42%. Volume still anchored by the majors: $BTC 34.24M, $ETH still heavy. Rotation feels active, but the move is still very selective.
0 · Reply
Filvul
Filvul Jul. 8 at 2:00 PM
$ALLO
0 · Reply
LVUP
LVUP Jul. 8 at 5:08 AM
$ALLO
0 · Reply
AS1980
AS1980 Jul. 7 at 1:43 PM
$ALLO endless..
0 · Reply
dflipflop
dflipflop Jul. 6 at 10:59 PM
$ALLO took an initial position here today.
0 · Reply
Unburdened
Unburdened Jul. 2 at 3:17 PM
$ALLO another great day
0 · Reply
alwayscheaper
alwayscheaper Jun. 30 at 8:46 PM
$ALLO feels like shorts have re entered today 😕
0 · Reply
Filvul
Filvul Jun. 30 at 8:21 PM
$ALLO Amazing!
0 · Reply
AS1980
AS1980 Jun. 30 at 7:33 PM
$ALLO 14m volume ? So strange
0 · Reply
LVUP
LVUP Jun. 30 at 1:22 PM
$ALLO new ceo new updates
0 · Reply
Filvul
Filvul Jun. 30 at 8:44 AM
$ALLO Do we expect any update from Allo 329 from today's conference?
1 · Reply
Merlintrader
Merlintrader Jun. 30 at 5:36 AM
$ALLO Allogene Therapeutics ($ALLO) Stock Hub: Off-the-Shelf CAR-T After the ALPHA3 Interim Readout https://www.merlintrader.com/allogene-therapeutics-stock-hub/
0 · Reply
Rilcol004
Rilcol004 Jun. 29 at 9:47 PM
$ALLO 😊
0 · Reply
x_pressionist
x_pressionist Jun. 29 at 7:03 PM
$ALLO Let’s see that squeeze now! 😎
0 · Reply
Filvul
Filvul Jun. 29 at 2:59 PM
$ALLO
0 · Reply
JHisai
JHisai Jun. 29 at 2:27 PM
$ALLO
0 · Reply
stopwatchinme
stopwatchinme Jun. 29 at 2:00 PM
$ALLO slowly claiming,$FITY on the watch.
0 · Reply
alwayscheaper
alwayscheaper Jun. 26 at 9:32 PM
$ALLO where did all that volume come from ????
1 · Reply
Filvul
Filvul Jun. 26 at 6:56 PM
$ALLO
0 · Reply
OB1_Whale
OB1_Whale Jun. 25 at 7:21 PM
$CYDY after researching stock prices of every company partnered with $NTRA i found that $ALLO has the cheapest stock price of any company working with them. It’s $700M market cap priced at $2 a share. Now that CYDY is partnered with $NTRA, it becomes the lowest of any company they have ever done business with. At $340M market cap and $0.22 a share.
2 · Reply